LN Robotics Inc.

Based in Seoul South Korea, and founded in 2019, LN Robotics Inc. specializes in developing advanced medical robotics, emphasizing the AVIAR system, which enhances cardiovascular interventions with precision and safety. LN Robotics Inc. headquartered in Seoul, South Korea, focuses on creating medical robots for healthcare professionals.

The company has successfully completed 4 deals, with its most recent funding round occurring on July 9, 2024, during which it raised KRW 20 billion in Series B funding led by LB Investment. The company has also attracted investments from the Industrial Bank of Korea and KB Investment, along with returning investors, Mirae Asset Venture Investment and STIC Ventures. No information about subsidiaries or previous ventures by the founder is available. LN Robotics Inc.

specializes in the development and implementation of advanced medical robotics, particularly the AVIAR (Advanced Vascular Intervention Assist Robot). This system is Korea's first cardiovascular intervention assist robot designed to enhance the precision and safety of Percutaneous Coronary Interventions (PCI). The AVIAR incorporates advanced mechanisms and artificial intelligence to reduce radiation exposure for both clinicians and patients while improving clinical outcomes. LN Robotics collaborates with major healthcare institutions, including Asan Medical Center, to optimize its technologies based on extensive clinical data and real-world surgical practices, serving a diverse client base that includes large hospitals throughout South Korea.

LN Robotics generates revenue primarily through direct sales of its medical robots to hospitals and healthcare providers, operating under a B2B transaction structure. The sales model is centered on significant, one-time purchase agreements, which may be supplemented by maintenance contracts to ensure the ongoing functionality of their robotic systems. Given the high cost of medical technology, the flagship product, AVIAR, is positioned as a crucial tool for surgical departments, facilitating substantial transaction values. Specific pricing information is not disclosed, but the company maintains ongoing relationships with key healthcare partners, emphasizing innovative solutions for cardiovascular care.

LN Robotics Inc. plans to leverage its recent Series B funding of KRW 20 billion, raised on July 9, 2024, to expand its product offerings and market reach. The company aims to develop new products and enhance existing technologies focusing on the AVIAR system. Additionally, LN Robotics Inc.

is targeting international expansion into markets where advanced medical technologies are in demand, although specific regions and timelines for these initiatives have not been disclosed. The funding will support these strategic initiatives, enabling the company to further its impact in the medical robotics field.